Crossmark

SRT3025-loaded cell membrane hybrid liposomes (3025@ML) enhanced anti-tumor activity of Oxaliplatin via inhibiting pyruvate kinase M2 and fatty acid synthase

Crossref DOI link: https://doi.org/10.1186/s12944-025-02431-x

Published Online: 2025-01-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Xiaobin

Li, Shulin

Li, Zichen

Lin, Zhuona

Wang, Zhifeng
Funding

Funding for this research was provided by:

Sanming Project of Medicine in Shenzhen Nanshan (SZSM202103003)

Major Scientific and Technological Project of the Health System in Nanshan Shenzhen (NSZD2024062)
License Information

Text and Data Mining valid from 2025-01-17

Version of Record valid from 2025-01-17
More Information

Article History

Received: 5 July 2024

Accepted: 6 January 2025

First Online: 17 January 2025

Declarations

:

: Ethical approval was obtained from the Guangdong Medical Laboratory Animal Center Ethical Committee (Approval number: C202205-24 and D202410-5). All animal procedures were performed in accordance with the relevant ethical guidelines.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below